A new approach to cancer target screening


A new approach to cancer target screening

BerGenBio’s ‘ask the cell’ technology could potentially change cancer treatment as we know it. With an expanding patent portfolio and library of trade secrets behind it, what challenges does the startup biotech company face in bringing its first drugs to market?

LSIPR asked chief executive Richard Godfrey.

Cancer is the leading cause of death in Europe: a third of people living there will die from the disease. Improvements in treatments are making it easier to manage, and more people are surviving their cancers.

These days the majority of cancer fatalities are a result of cancer spread (metastasis) and metastatic tumours are often drug-resistant.

BerGenBio, Richard Godfrey, cancer, CellSelect, IP strategy